Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Total Liabilities
Everything the company owes to creditors and other parties.
Tenax Therapeutics, Inc.NASDAQ: TENX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 206.6% from a year ago
Total liabilities stood at $8.49M at the end of Q1 FY2026, up 206.6% from a year earlier and up 18.6% from the prior quarter. Over 3 fiscal years it compounded at +55.3% a year.
Context
- Total liabilities amounted to 6.9% of total assets at the end of Q1 FY2026, up 4.4 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +206.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.16M USD
- Year-over-year change
- +52.5%
- 4-year CAGR
- +42.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.16M | +52.5% |
| FY2024 | 2024-12-31 | 4.69M | +30.9% |
| FY2023 | 2023-12-31 | 3.59M | +87.6% |
| FY2022 | 2022-12-31 | 1.91M | +9.4% |
| FY2021 | 2021-12-31 | 1.75M | — |
Total Liabilities vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 total liabilities of $8.49M is the 6th highest of the 7 companies compared; the peer median is $23.08M.
- Its year-over-year change of +206.6% is the 2nd highest of 7, against a peer median of -14.3%.
- Total liabilities amounts to 6.9% of total assets for TENX, versus a peer median of 33.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $296.65B | +474318.1% | +47.0% | 312.0% | |
| Mar 2026 | $54.59M | -0.1% | -28.3% | 38.7% | |
| Jun 2026 | $23.43M | +29.3% | +2.4% | 9.8% | |
| Mar 2026 | $22.73M | -62.6% | +68.4% | 58.6% | |
| Mar 2026 | $17.36M | -79.1% | -53.2% | 27.3% | |
| Mar 2026 | $8.49M | +206.6% | +55.3% | 6.9% | |
| Mar 2026 | $5.73M | -28.5% | +7.3% | 6.6% | |
| Peer median (excluding TENX) | $23.08M | -14.3% | +4.9% | 33.0% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.